CTI BioPharma Corp. (CTIC)

CTI BioPharma (CTIC) Stock Price & Analysis


CTIC Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.32 - $7.80
Previous Close$4.44
Average Volume (3M)3.02M
Market Cap
Enterprise Value$555.37M
Total Cash (Recent Filing)$79.94M
Total Debt (Recent Filing)$49.96M
Price to Earnings (P/E)-5.2
May 04, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding126,894,203
10 Day Avg. Volume2,131,701
30 Day Avg. Volume3,022,518
Standard Deviation0.31
Financial Highlights & Ratios
Price to Book (P/B)-17.16
Price to Sales (P/S)21.20
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-6.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.29
Enterprise Value/Gross Profit11.01
Enterprise Value/Ebitda-7.22
Price Target Upside154.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was CTI BioPharma Corp.’s price range in the past 12 months?
CTI BioPharma Corp. lowest stock price was $3.32 and its highest was $7.80 in the past 12 months.
    What is CTI BioPharma Corp.’s market cap?
    Currently, no data Available
    When is CTI BioPharma Corp.’s upcoming earnings report date?
    CTI BioPharma Corp.’s upcoming earnings report date is May 04, 2023 which is in 44 days.
      How were CTI BioPharma Corp.’s earnings last quarter?
      CTI BioPharma Corp. released its earnings results on Mar 06, 2023. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.096 by -$0.044.
        Is CTI BioPharma Corp. overvalued?
        According to Wall Street analysts CTI BioPharma Corp.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does CTI BioPharma Corp. pay dividends?
          CTI BioPharma Corp. does not currently pay dividends.
          What is CTI BioPharma Corp.’s EPS estimate?
          CTI BioPharma Corp.’s EPS estimate is -$0.1.
            How many shares outstanding does CTI BioPharma Corp. have?
            CTI BioPharma Corp. has 131,835,890 shares outstanding.
              What happened to CTI BioPharma Corp.’s price movement after its last earnings report?
              CTI BioPharma Corp. reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.096. Following the earnings report the stock price went down -10.223%.
                Which hedge fund is a major shareholder of CTI BioPharma Corp.?
                Among the largest hedge funds holding CTI BioPharma Corp.’s share is Perceptive Advisors LLC. It holds CTI BioPharma Corp.’s shares valued at N/A.


                  CTI BioPharma Stock Smart Score

                  The CTI BioPharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  CTI BioPharma Corp.

                  CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Adicet Bio
                  PureTech Health
                  4D Molecular Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis